
GEHC Stock Forecast & Price Target
GEHC Analyst Ratings
Bulls say
GE HealthCare Techs is supported by a stronger-than-expected Q3'26 print, with 6.2% organic revenue growth, adjusted EPS above consensus, and a book-to-bill of 1.03x that appears to reflect backlog conversion more than demand softness. Broad-based strength across Imaging, Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, especially PCS at +8.8% organic versus expectations for decline, reduces a major overhang and supports the view that the 2H'26 inflection is real. Management’s raised FY26 guide across organic growth, margins, EPS, and free cash flow, plus a 12% y/y backlog increase and improving pipeline, gives a credible path for momentum into 2027.
Bears say
GE HealthCare Techs is facing a negative setup because its growth depends on slower-than-expected backlog conversion, weaker commercial execution, and a sluggish shift toward recurring revenue, even though recurring streams make up about half of sales through servicing, diagnostics, and digital offerings. Tariffs and inflation are already pressuring profitability, with inflation a ~170bps headwind to adjusted EBIT margin in 3Q26 and management expecting FY27 impacts similar to FY26, limiting gross margin improvement and offsetting benefits from cost cuts and SOFIE. On top of that, low-single-digit revenue growth in the bear case, China weakness, hospital capital budget pressure, competition, supply-chain risk, and regulatory exposure all threaten earnings growth and shareholder returns.
This aggregate rating is based on analysts' research of GE HealthCare Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
GEHC Analyst Forecast & Price Prediction
Start investing in GEHC
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About GE HealthCare Technologies Inc (GEHC) Forecast
GEHC Analyst Forecast & Price Prediction
Start investing in GEHC
Order type
Buy in
Order amount
Est. shares
0 shares